Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tvardi TherapeuticsLTS:0HTC 8 Cyclically Adjusted PS Ratio is 0.12 as of Sep. 15, 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 532 Biotechnology companies, Tvardi Therapeutics ranks worse than 187969.74% on this metric.
Tvardi Therapeutics (LTS:0HTC) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Tvardi Therapeutics Cyclically Adjusted PS Ratio Related Terms
Tvardi Therapeutics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Tvardi Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tvardi Therapeutics Cyclically Adjusted PS Ratio Chart
LTS:0HTC vs PVCT, CLRB, DYAI: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Tvardi Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tvardi Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Tvardi Therapeutics's Cyclically Adjusted PS Ratio falls into.
Tvardi Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Tvardi Therapeutics does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.
What does a Cyclically Adjusted PS Ratio of 0.12 mean?
Tvardi Therapeutics (LTS:0HTC) has a Cyclically Adjusted PS Ratio of 0.12 as of Sep. 15, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #999999 out of 532 companies in the Biotechnology industry.
Is Tvardi Therapeutics' Cyclically Adjusted PS Ratio too high?
Tvardi Therapeutics' current Cyclically Adjusted PS Ratio is 0.12. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.78. Tvardi Therapeutics' value of 0.12 is 97.9% below this industry median. Based on the distribution chart, Tvardi Therapeutics ranks #999999 out of 532 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tvardi Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Cyclically Adjusted PS Ratio compare to PVCT and CLRB?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #999999 out of 532 companies for Cyclically Adjusted PS Ratio. This places Tvardi Therapeutics in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.78. Tvardi Therapeutics' value of 0.12 is 97.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.78, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tvardi Therapeutics's current Cyclically Adjusted PS Ratio of 0.12 is 97.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current Cyclically Adjusted PS Ratio is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Cyclically Adjusted PS Ratio of 0.12. The current Cyclically Adjusted PS Ratio is 0.12 and 97.9% below the Biotechnology industry median of 5.78. Tvardi Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Cyclically Adjusted PS Ratio is 0.12 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
8GF Score
Get the complete analysis for LTS:0HTC
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTC has been successfully added to your 
